On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...